25H-NBOMe

25H-NBOMe, also known as NBOMe-2C-H, is a derivative of the phenethylamine hallucinogen 2C-H, which acts as a highly potent full agonist for the human 5-HT2A receptor.

Use and effects The active dose range of 25H-NBOMe in humans has not been reported and hence is unknown. This is in notable contrast to many other NBOMe drugs.

Toxicity and harm potential

Neurotoxic and cardiotoxic actions

Emergency treatment

Interactions

Pharmacology Pharmacodynamics + Target Affinity (Ki, nM) 5-HT1A 4,520–6,973 (Ki)28,400 ()52% () 5-HT1B 5-HT1D 5-HT1E 5-HT1F 5-HT2A 2.83–49.4 (Ki)11.0–490 ()38–144% () 5-HT2B 62.9 (Ki)340–463 ()11–38% () 5-HT2C 16.4–130 (Ki)13.8 ()96% () 5-HT3 5-HT4 5-HT5A 5-HT6 5-HT7 α1A 550 α1B, α1D α2A 530 α2B, α2C β1–β3 D1 14,000 D2 7,700 D3 20,000 D4, D5 H1 4,100 H2–H4 M1–M5 I1 σ1, σ2 MOR DOR KOR >20,000 (Ki) (mouse)1,400–1,500 (Ki) (rat)6,100 () (mouse)3,000 () (rat)>10,000 () (human)53% () (mouse)37% () (rat) 2,220–2,300 (Ki)2,080–12,000 () () 5,500–16,300 (Ki)3,650–10,000 () () 35,000–81,400 (Ki)120,000 () () Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs:

25H-NBOMe acts as an agonist of the serotonin 5-HT2 receptors.

Its affinity for the serotonin 5-HT2A receptor (Ki = 2.83nM) was 133-fold higher than that of 2C-H and 24-fold higher than that of 25H-NB (N-benzyl-2C-H), whereas it was 4-fold lower than that of 2C-I and 64-fold lower than that of 25I-NBOMe. In terms of activational potency at the receptor, the drug's potency ( = 15.3nM) was 67-fold higher than that of 2C-H, whereas it was 6-fold lower than that of 2C-I and 35-fold lower than that of 25I-NBOMe. Hence, unlike other NBOMe drugs, 25H-NBOMe appears to have affinity and activational potency at the serotonin 5-HT2A receptor more in line with the 2C psychedelics like 2C-I and much lower than NBOMe drugs like 25I-NBOMe.

25H-NBOMe produces hyperlocomotion, a stimulant-like effect, and the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. Its potency in inducing the head-twitch response was variably lower than that of other NBOMe drugs like 25I-NBOMe and 25B-NBOMe. Conversely, its potency in inducing hyperlocomotion was about the same as that of 25I-NBOMe and 25C-NBOMe. The drug has also been found to produce antidepressant-like effects in rodents. 25H-NBOMe has shown reinforcing effects in rodents. This included conditioned place preference (CPP) and self-administration.

History 25H-NBOMe was first described in the scientific literature by Ralf Heim at the Free University of Berlin by 2003.

Society and culture Legal status Canada 25H-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.

Sweden The Riksdag added 25H-NBOMe to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 1, 2013, published by Medical Products Agency (MPA) in regulation LVFS 2013:15 listed as 25H-NBOMe, and 2-(2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin.

United Kingdom

United States 25H-NBOMe is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

25H-NBOMe

Bron en licentie